Virtual Library
Start Your Search
S. Bernal
Author of
-
+
P3.02 - Biology/Pathology (ID 620)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.02-056 - EGFR Mutation Profile of NSCLC Patients Tested at the Lung Center of the Philippines (ID 9992)
09:30 - 09:30 | Author(s): S. Bernal
- Abstract
Background:
EGFR mutation testing has been established as a companion diagnostic for targeted therapy of Non-Small Cell Lung Carcinoma (NSCLC). The Lung Center of the Philippines (LCP) established a program with pharmaceutical companies (Roche and Astra-Zeneca) to conduct free EGFR testing for several NSCLC patients. This report aims to showcase the EGFR mutation profiles observed and their implication to targeted therapy among Filipino patients.
Method:
Tumor block specimens from patients clinically diagnosed with NSCLC at stages II to IV with at least 5% density of histopathologic tumor cells were extracted with DNA and subjected to EGFR mutation analysis using the Roche EGFR mutation detection kit and Cobas Quantitative Real Time PCR. The laboratory test was UKNEQAS certified to assure the quality and validity of results.
Result:
EGFR positive specimens were detected at 42.6% (260/611) in cohort A and 42.4% (42/99) in cohort B close to the values earlier reported by our laboratory (i.e., 47.5%). For A, 14 mutation types were detected. For B, only 7 were detected. The dominant mutations in both A and B were Exon 19 Deletion (i.e., 58.8% and 54.5% respectively) and Exon 21 L858R (i.e., 27.7% and 21.4% respectively). The Exon 20 T790M, a mutation that confers TKI resistance, was detected in both cohorts associated with Exon 19 Deletion (i.e., 1.9% in A and 4.8% in B). The same mutation was also detected in A associated with Exon 21 L858R but at low rate (i.e., 0.8%). Gender-wise, there were twice as much females as males that were positive for the EGFR mutation. The average age were 60.1 for males and 59.8 for females.
Conclusion:
The EGFR mutation profile showed that more mutation types are detected with sample size increase; the dominant mutation occurs in Exon 19 Deletion with count twice as much as Exon 21 L858R. The Exon 20 T790M mutation was detected in conjunction with these two mutations at less than 5%.
